857478-11-6

Basic information

• Product Name: Valeramide, 2-amino-N,N,4-trimethyl- (5CI)
• Synonyms: Valeramide, 2-amino-N,N,4-trimethyl- (5CI)
• CAS NO: 857478-11-6
• Molecular Formula: C8H18N2O
• Molecular Weight: 158.24132
• Mol File: 857478-11-6.mol
• Article Data: 11

Chemical Properties

• Appearance: /
• CAS DataBase Reference: Valeramide, 2-amino-N,N,4-trimethyl- (5CI)(CAS DataBase Reference)
• NIST Chemistry Reference: Valeramide, 2-amino-N,N,4-trimethyl- (5CI)(857478-11-6)
• EPA Substance Registry System: Valeramide, 2-amino-N,N,4-trimethyl- (5CI)(857478-11-6)

Safety Data

• Hazardous Substances Data: 857478-11-6(Hazardous Substances Data)

Upstream product

• 108112-32-9 ((R)-1-dimethylcarbamoyl-3-methyl-butyl)-carbamic acid tert-butyl ester 
• 61-90-5 L-leucine 
• 13139-15-6 N-tert-butoxycarbonyl-L-leucine 
• 2018-66-8 Z-Leu-OH 
• 506-59-2 N,N-dimethylammonium chloride 
• 72080-89-8 N²-(tert-butoxycarbonyl)-N,N-dimethyl-L-leucinamide 
• 83892-00-6 N-benzyloxycarbonyl-L-leucine dimethylamide 
• 94580-89-9 N-benzyloxycarbonyl-L-leucine 2,4,6-trichlorophenyl ester 

Downstream Products

• 1352966-70-1 (S)-2-((R)-2-hydroxy-2-methyl-1-phenylpropylamino)-N,N,4-trimethylpentanamide 
• 1352966-71-2 (S)-2-((S)-2-hydroxy-2-methyl-1-phenylpropylamino)-N,N,4-trimethylpentanamide 
• 83892-03-9 N-benzyloxycarbonyl-L-phenylalanyl-L-leucine dimethylamide 

Relevant articles and documents

Peptidomimetics for Targeting Protein-Protein Interactions between DOT1L and MLL Oncofusion Proteins AF9 and ENL

MLL-fusion proteins, AF9 and ENL, play an essential role in the recruitment of DOT1L and the H3K79 hypermethylation of MLL target genes, which is pivotal for leukemogenesis. Blocking these interactions may represent a novel therapeutic approach for MLL-rearranged leukemia. Based on the 7 mer DOT1L peptide, a class of peptidomimetics was designed. Compound 21 with modified middle residues, achieved significantly improved binding affinities to AF9 and ENL, with KD values of 15 nM and 57 nM, respectively. Importantly, 21 recognizes and binds to the cellular AF9 protein and effectively inhibits the AF9-DOT1L interactions in cells. Modifications of the N- and C-termini of 21 resulted in 28 with 2-fold improved binding affinity to AF9 and much decreased peptidic characteristics. Our study provides a proof-of-concept for development of nonpeptidic compounds to inhibit DOT1L activity by targeting its recruitment and the interactions between DOT1L and MLL-oncofusion proteins AF9 and ENL.

Ring-Opening polymerization of lactides catalyzed by natural Amino-Acid based zinc catalysts

A series of chiral NNO-tridentate Schiff base ligands derived from natural amino acids were reacted with zinc(bis-trimethylsilylamide)2 to provide metal complexes which have been fully characterized. One of these derivatives was further reacted

COMPOUNDS AND METHODS FOR INHIBITING THE INTERACTION OF BCL PROTEINS WITH BINDING PARTNERS

-